Enantiomeric Propanolamines as selectiveN-Methyl-d-aspartate 2B Receptor Antagonists
- 23 August 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (18) , 5506-5521
- https://doi.org/10.1021/jm8002153
Abstract
Enantiomeric propanolamines have been identified as a new class of NR2B-selective NMDA receptor antagonists. The most effective agents are biaryl structures, synthesized in six steps with overall yields ranging from 11−64%. The compounds are potent and selective inhibitors of NR2B-containing recombinant NMDA receptors with IC50 values between 30−100 nM. Potency is strongly controlled by substitution on both rings and the centrally located amine nitrogen. SAR analysis suggests that well-balanced polarity and chain-length factors provide the greatest inhibitory potency. Structural comparisons based on 3D shape analysis and electrostatic complementarity support this conclusion. The antagonists are neuroprotective in both in vitro and in vivo models of ischemic cell death. In addition, some compounds exhibit anticonvulsant properties. Unlike earlier generation NMDA receptor antagonists and some NR2B-selective antagonists, the present series of propanolamines does not cause increased locomotion in rodents. Thus, the NR2B-selective antagonists exhibit a range of therapeutically interesting properties.Keywords
This publication has 75 references indexed in Scilit:
- Expression and characterization of soluble amino‐terminal domain of NR2B subunit of N‐methyl‐d‐aspartate receptorProtein Science, 2005
- The Many Roles of Computation in Drug DiscoveryScience, 2004
- Glutamate Receptor GatingCritical Reviews™ in Neurobiology, 2004
- Pharmacological Characterization of Ro 63-1908 (1-[2-(4-Hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a Novel Subtype-Selective N-Methyl-d-Aspartate AntagonistThe Journal of Pharmacology and Experimental Therapeutics, 2002
- State‐dependent NMDA receptor antagonism by Ro 8‐4304, a novel NR2B selective, non‐competitive, voltage‐independent antagonistBritish Journal of Pharmacology, 1998
- Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rulesJournal of Computational Chemistry, 1996
- Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94Journal of Computational Chemistry, 1996
- Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactionsJournal of Computational Chemistry, 1996
- Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94Journal of Computational Chemistry, 1996
- Structures and properties of seven isoforms of the NMDA receptor generated by alternative splicingBiochemical and Biophysical Research Communications, 1992